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Abstract
Inappropriate activation of complement on the vascular endothelium of specific organs, or systemically, underlies the
etiology of a number of diseases. These disorders include atypical hemolytic uremic syndrome, membranoproliferative
glomerulonephritis, atherosclerosis, age-related macular degeneration, diabetic retinopathy, and transplant rejection.
Inhibition of the terminal step of complement activation, i.e. formation of the membrane attack complex, using CD59 has
the advantage of retaining the upstream processes of the complement cascade necessary for fighting pathogens and
retaining complement’s crucial role in tissue homeostasis. Previous studies have shown the necessity of membrane
targeting of soluble CD59 in order for it to prove an effective inhibitor of complement deposition both in vitro and in vivo.I n
this study we have generated an in vivo model of human complement activation on murine liver vascular endothelium. This
model should prove useful for the development of anti-complement therapies for complement-induced pathologies of
vascular endothelium. Using this model, we have demonstrated the viability of a non membrane-targeted soluble CD59 to
significantly inhibit complement deposition on the endothelium of murine liver vasculature when expressed in vivo from an
adenovirus. This result, unanticipated based on prior studies, suggests that the use of non membrane-targeted sCD59 as an
anti-complement therapy be re-visited.
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Introduction
Complement is a key component of innate immunity [1].
Activation of complement results in the generation of anaphyla-
toxins - pleiotropic effector molecules that mediate both
inflammatory processes, such as chemoattraction, vasodilation
and vasopermeability. In addition, anaphylatoxins mediate non-
inflammatory processes, such as tissue regeneration, lipid metab-
olism, and synapse formation (reviewed in [2]). Activation of
complement terminates in the formation of a pore on the surface
of target cells referred to as the membrane attack complex (MAC),
resulting in cell lysis.
Inappropriate activity of the complement system, specifically on
endothelial cells, results in a number of diseases. For example,
damage and detachment of the endothelium due to abnormal
complement activity has been documented in atypical hemolytic
uremic syndrome (aHUS) [3]. Both types of membranoprolifera-
tive glomerulonephritis (MPGN), type I and dense deposit disease
(MPGN type II), are characterized by the presence of complement
proteins within the subendothelial dense-deposit along the
glomerular basement membrane [4]. Dense deposit disease has
been linked to a deficiency in the complement regulator, Factor H
[5]. Transgenic mice expressing a negative regulator of comple-
ment, referred to as protectin (CD59), on the endothelium are
protected against atherosclerosis [6]. Age-related macular degen-
eration (AMD) has been tightly linked to polymorphisms in various
complement genes [7], and complement proteins such as MAC
have been observed to be deposited on choroidal endothelial cells
[8]. Complement proteins have also been documented to be
deposited on the choriocapillaris of patients with diabetic
retinopathy, as well as in the retinal vessels of diabetic subjects
[9]. These vessels also exhibited a significant reduction in
expression of the complement regulatory proteins, decay acceler-
ating factor (CD55) and CD59. Hyperacute rejection of organ
transplantation, mainly the liver and kidney, has shown evidence
of complement activity on the endothelium, and is considered a
key reason for transplant rejection [10]. An ex vivo perfusion
simulation of xenotransplantation using normal human blood in
porcine liver has indicated intralobular hemorrhage and complete
loss of hepatic function within hours of complement component 3
and MAC deposition on endothelial cells [11]. Ischemia/
reperfusion (I/R) injury, a complication of a number of
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infarction, sepsis and shock, has been shown to be mediated by
complement-induced damage of endothelial cells of the vascula-
ture and a number of studies have shown the effectiveness of
complement inhibitors to reduce I/R injury (reviewed in [12]).
CD59 is a glycosylphosphatidyl inositol (GPI)-anchored mem-
brane inhibitor of MAC formation on cellular membranes [13,14].
Studies have shown that while the activity of a soluble version of
the inhibitor of MAC formation (sCD59) is one hundred times
lower than that of GPI-linked CD59 in the absence of human
serum in vitro [15], in the presence of serum concentrations as high
as 50% the activity of sCD59 was 10-fold higher than that of GPI-
linked CD59. These studies suggest sCD59 as a viable alternative
to the membrane-bound form of CD59 in vivo. Multiple groups,
however, have reported that recombinant sCD59 alone is a poor
therapeutic molecule, as they have not observed any significant
protection from complement-mediated damage to cells or tissues
either in in vitro or in vivo. To overcome this poor performance,
sCD59 chimeras that target recombinant sCD59 to the cell
membrane have been developed. A soluble form of rat CD59
fused with a plasma membrane-addressing peptide (APT542) has
been shown to reduce MAC activity in vivo in a rat model of
rheumatoid arthritis [16]. When rat sCD59 is delivered as a
recombinant Fc fusion protein, protection against MAC-induced
damage has been successful in both a model of antigen-induced
arthritis and of laser-induced choroidal neovascularization [17,18].
Soluble CD59 fused with either a fragment of complement
receptor 2 which targets the protein to activated complement
proteins deposited on cell membranes, or to an IgG, provided
protection from MAC on chinese hampster ovary cells in vitro
[19,20].
In contrast to the above in vivo studies which involved delivery of
a recombinant membrane-targeting form of sCD59, we have
recently shown that a membrane-independent sCD59 when
expressed in vivo in murine ocular tissue via an adenovirus or
adeno-associated virus (AAV) vector can significantly reduce MAC
deposition and laser-induced choroidal neovascularization in a
mouse model of neovascular AMD [21]. We postulated that the
success of that study may be explained in part by constitutive
expression of high concentrations of sCD59 in the closed ocular
environment. To determine whether this gene therapy approach
was also applicable to other tissues, we sought to examine whether
we could inhibit MAC deposition on endothelial cells of murine
liver vasculature in vivo using sCD59. To address this, we generated
an in vivo model of human complement deposition on liver vascular
endothelium. We employed an approach similar to that previously
described by us in which we generated an ex vivo model of human
MAC deposition on murine retinal pigment epithelial cells (RPE)
[22], a model which has proven useful for validating the potential
of human membrane-linked complement regulators (CD59 [22],
CD55 [23], and CD46 [24]) to protect RPE cells against attack by
human complement. By infusion of an endothelial cell-specific
antibody followed by human serum, we have been able to achieve
human MAC deposition on the endothelium of murine liver
vasculature. This model should prove useful in the rapid testing of
anti-complement therapies for the treatment of complement-
mediated diseases of the vasculature. We then tested and
confirmed the capacity of an adenovirus-delivered sCD59 to
protect liver vascular endothelium from human MAC deposition.
Our study suggests that the use of a membrane-independent
sCD59 as an anti-complement therapy for complement-associated
diseases should be re-visited.
Results
Deposition of human membrane attack complex on
murine endothelial cells ex vivo
To determine whether human complement is activated by
murine endothelial cells, an explant of murine aorta was incubated
with either an antibody against murine platelet/endothelial cell
adhesion molecule (mPECAM-1) or a generic anti-mouse (GAM)
antibody and subsequently incubated with either normal human
serum (NHS) or heat inactivated NHS (HI-NHS). The tissue was
subsequently stained for the presence of the membrane attack
complex (MAC) deposited on cell surfaces, using an antibody
against sC5b-9. In the presence of either NHS alone (data not
shown) or GAM+NHS, low levels of MAC staining were observed
on individual endothelial cells of the luminal surface (Figure 1).
However, staining was limited to only a few patches of cells. Aorta
that had been incubated with mPECAM-1+NHS exhibited
significantly more robust and homogeneous deposition of MAC
on endothelial cells across the luminal surface (Figure 1). Aortal
tissue incubated with HI-NHS subsequent to incubation with
mPECAM-1 antibody did not deposit MAC on its surface
(Figure 1).
Intracardial delivery of mPECAM-1 antibody results in
binding of antibody to a variety of murine tissues in vivo
Due to the need for an endothelial cell surface antibody for
activation of human complement by murine endothelial cells, we
determined the feasibility of intracardial delivery of mPECAM-1
antibody into the systemic vasculature of mice. Four hours post-
intracardial injection of either the mPECAM-1 antibody (or a
GAM antibody), tissues were harvested and stained with a Cy3-
conjugated goat anti-hamster antibody. mPECAM-1 staining was
detected on a variety of tissues, including the liver, retina, choroid
and aorta (Figure 2). In the liver, intracardial injection of
mPECAM-1 antibody resulted in antibody binding to endothelial
cells of both the sinusoids and larger blood vessels (arteries and
veins). In the posterior eyecup, mPECAM-1 antibody was detected
on endothelial cells of the retinal vasculature, as well as on those of
the choriocapillaris of the choroid. To facilitate detection of
antibody binding to endothelial cells of the choriocapillaris, which
could be hampered by the presence of choroidal pigment,
mPECAM-1 antibody was delivered intracardially to Balb/C
mice and choroidal/RPE flatmounts prepared. With this proce-
dure, extensive binding of mPECAM-1 antibody binding of the
choriocapillaris could be observed. In the aorta, robust staining of
endothelial cells of the luminal surface was observed. Intra-cardial
delivery of GAM indicated no staining specific to the endothelium
in the liver, retina, choroid, or aorta (Figure 2).
Intracardial delivery of mPECAM-1 and NHS results in
deposition of human MAC on endothelial cells of the
liver
Four hours post-intracardial delivery of mPECAM-1 antibody,
mice were perfused with either NHS or HI-NHS. 15 minutes post
serum infusion, tissues (liver, choroid, and retina) were harvested
and stained for deposition of human MAC using an antibody
against sC5b-9. Staining of liver sections from mice infused with
mPECAM-1 and NHS exhibited prominent MAC deposition on
the endothelial cells of sinusoids and larger blood vessels
(Figure 3A). Liver sections of mice perfused with mPECAM-1
antibody and NHS (mPECAM-1+NHS) indicated significantly
higher levels of MAC deposition relative to liver sections of control
mice perfused with mPECAM-1 antibody and HI-NHS (mPE-
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intensity, a 3.8-fold increase in MAC deposition was observed in
the livers of mice injected with mPECAM-1+NHS (1.81610
7 IU)
relative to the livers of mice injected with mPECAM-1+HI-NHS
(0.48610
7 IU, p,0.01). Deposition of MAC was not detected in
any of the other tissues examined (data not shown).
Intraperitoneal injection of an adenovirus expressing
human soluble CD59 protects against human MAC
deposition on endothelial cells of murine liver
vasculature
Intraperitoneal injection of an adenovirus expressing green
fluorescent protein (GFP, AdCAGGFP) results in GFP expression
mainly along the peritoneal membrane of the liver, with some
expression of GFP by a few cells within the liver (Figure 4). A
similar virus was generated expressing human soluble CD59
(sCD59), which lacks the C-terminal 26 amino acids encoding the
signal sequence for attachment of the GPI anchor (Ad-
Figure 1. Cell-specific antibody is required for deposition of
human MAC on endothelial cells of murine aorta ex vivo.
Representative images are shown of flatmounts of murine aorta stained
for human MAC following incubation with normal human serum and
either a generic anti-mouse (GAM) antibody or mPECAM-1 antibody. As
a control, staining of aorta for MAC was performed following incubation
with mPECAM-1 antibody and heat-inactivated NHS (HI-NHS). While
treatment with GAM and NHS results in only a few endothelial cells
staining for MAC across the lumen of the aorta, incubation with
mPECAM-1 antibody and NHS results in more extensive and uniform
staining of endothelial cells across the tissue. Insets show higher
magnification of boxed regions. Aorta incubated with mPECAM-1
antibody and HI-NHS shows little or no MAC staining.
doi:10.1371/journal.pone.0021621.g001
Figure 2. Intracardial delivery of mPECAM-1 antibody permits
binding to a variety of murine tissues. Liver: In the liver, mPECAM-
1 antibody binds endothelial cells along the sinusoids (arrowhead), as
well as those of larger blood vessels (arrow). Retina: In the posterior
eyecup, mPECAM-1 binds endothelia of the choriocapillaris (arrowhead)
and retinal vasculature (arrow). Choroid: A flatmount of the choroid/RPE
harvested from Balb/C mice injected intracardially with mPECAM-1
antibody shows more clearly binding of the antibody to the choroidal
endothelium. Aorta: In the aorta, mPECAM-1 antibody is observed to
bind the endothelial cell layer on the luminal surface (higher
magnification of boxed region shown in inset). Intracardial delivery of
a generic anti-mouse (GAM) antibody does not result in labeling of
endothelial cells in any of the tissues. G, Ganglion Cell Layer; I/O, Inner/
Outer Nuclear Layer; C, Choroid.
doi:10.1371/journal.pone.0021621.g002
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AdCAGGFP by intraperitoneal injection and 7 days later injected
intracardially with mPECAM-1 antibody followed by NHS as
described above. 15 minutes after serum delivery, livers were
harvested and sections stained for deposition of human MAC.
While blood vessels and sinusoids of liver sections from mice
treated with AdCAGGFP stained strongly positive for MAC
(Figure 5A), blood vessels and sinusoids of liver sections from
AdCAGsCD59-injected mice indicated little or no MAC staining
(Figure 5A). Quantitation of staining indicated that the average
MAC staining intensity was reduced by 62.1% (p,0.01) in
AdCAGsCD59-injected mice relative to those injected with
AdCAGGFP. The average MAC staining intensity of liver sections
of the AdCAGsCD59-treated mice was 1.60610
7 IU relative to
4.23610
7 IU of those treated with AdCAGGFP (Figure 5B).
Because adenovirus has previously been shown to activate
mouse complement [25] and the sC5b-9 antibody used can detect
both mouse and human MAC, we performed a control
experiment to exclude the possibility that any of the MAC
deposited is from activated mouse complement. To address this,
we injected mice intraperitoneally with AdCAGGFP 7 days prior
to intracardial injection with mPECAM-1 antibody. Four hours
later, instead of NHS, mice were administered PBS
++ by
intracardial perfusion. 15 minutes following PBS
++ infusion, livers
were harvested and stained for MAC using the sC5b-9 antibody.
There was no MAC staining detected in any cell type in these
livers (data not shown), confirming that the MAC deposition
detected post-adenoviral injection in mPECAM-1+NHS treated
mice is formed from human, not mouse, complement.
AdCAGsCD59 protects against MAC deposition on
endothelial cells of blood vessels of the liver
While MAC deposition was observed on endothelial cells of
both the sinusoids and blood vessels, we were specifically interested
in the protection conferred by sCD59 in endothelial cells of the
blood vessels. Representative sections taken from livers of
AdCAGsCD59- and AdCAGGFP-injected mice indicated that
staining along the luminal surface of larger vessels in the
AdCAGsCD59-treated mice was discontinuous and less intense
relative to that of AdCAGGFP-injected mice (Figure 6A).
Quantitation of staining on the hepatic blood vessels of
AdCAGsCD59-injected mice indicated reduced MAC deposition
(41.4%, p,0.001) relative to those of AdCAGGFP-treated mice.
The average staining intensity per endothelial cell area in the livers
of AdCAGsCD59-injected mice was 251.27 IU/mm
2, while that of
the vessels of livers of AdCAGGFP-injected mice was 428.95 IU/
mm
2.
Figure 3. Intracardial delivery of mPECAM-1 and NHS results in
deposition of human MAC on endothelial cells of blood vessels
in murine liver. (A) Perfusion of liver with mPECAM-1 antibody and
NHS results in MAC deposition on endothelial cells of sinusoid canals
(arrowhead) and larger blood vessels (arrow). Liver perfused with
mPECAM-1 and HI-NHS exhibits significantly less MAC deposition. (B)
The average MAC staining intensity of livers of mice perfused with
mPECAM-1 antibody and NHS is 3.8-fold higher (**p,0.01) than the
staining intensity of those perfused with mPECAM-1 antibody and HI-
NHS (n=3).
doi:10.1371/journal.pone.0021621.g003
Figure 4. Intraperitoneal injection of an adenovirus expressing
GFP (AdCAGGFP) shows significant transduction of murine
liver at 7 days post-injection. A representative image of a transverse
section of mouse liver showing GFP transduction is presented. DAPI
stain of cell nuclei of the same liver section is also shown. GFP+DAPI
overlay shows that GFP expression was observed almost exclusively
along the peritoneal membrane, with a few cells within the liver
expressing GFP.
doi:10.1371/journal.pone.0021621.g004
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The only FDA approved therapeutics targeting complement
include an antibody against complement component 5 (eculizu-
mab) and C1 inhibitor, but there are a number of ongoing trials
investigating the safety and potency of complement regulators
(reviewed in [26]). These include a peptide antagonist of
complement component 3 (POT-4), an antibody against Factor
D (TNX-234), and an aptamer targeting complement component
5 (ARC1905). Unlike the above listed complement regulators,
CD59 specifically inhibits the terminal stage of complement
activation, i.e. MAC formation on the plasma membrane. CD59
binds the C5b-8 protein complex deposited on the membrane and
prevents the incorporation of multiple C9 molecules which are
required for formation of the pore [27]. Specifically targeting
MAC formation using CD59 has the advantage of keeping the
upstream processes of the complement pathway intact for the
purpose of fighting pathogens [28,29,30], as well as maintaining its
important roles in tissue homeostasis [31].
We have shown previously that human GPI-anchored CD59
delivered via an adenovirus vector to murine RPE cells can
provide robust protection to those cells against human MAC
deposition [22]. However, protection was only conferred to those
cells transduced by the adenovirus. In the plethora of disorders in
which a major role of complement activation has been implicated,
it is unlikely that a gene delivery vector will be available to
transduce the variety of cell types subject to complement attack.
We therefore elected to re-consider the capacity of a soluble
version of CD59 as an anti-complement therapy when adminis-
tered via a gene therapy approach. Soluble forms of CD59 have
been described previously, but have been shown to be inefficient
inhibitors of MAC both in vitro and in vivo [16,19]. Those authors
have speculated that sCD59’s ineffectiveness in vivo may be due to
its small size, which may make it more easily filtered by the renal
system, as well as its inability to associate with the membrane, the
site of MAC formation. We have recently shown, however, that
sCD59 delivered by either an adenovirus or an AAV vector to
murine ocular tissues can significantly reduce MAC deposition
and laser-induced choroidal neovascularization in a model of
neovascular AMD [21]. This result, unanticipated based on prior
studies, suggested that sCD59 warrants further investigation as a
treatment, not only for AMD and ocular disorders of complement,
but also for disturbances of complement activity affecting other
tissues.
Figure 5. Intraperitoneal injection of an adenovirus expressing
human sCD59 results in reduced deposition of human MAC on
endothelial cells of liver vasculature. (A) Representative micro-
graphs showing human MAC deposition on sinusoidal endothelial cells,
as well as the endothelial cells of blood vessels in livers of mice
perfused with mPECAM-1 antibody and NHS 7 days post-injection with
an adenovirus expressing either sCD59 (AdCAGsCD59) or GFP
(AdCAGGFP). Low and high magnification images are shown for each.
The intensity and area of MAC staining is reduced in the AdCAGsCD59-
treated mice. (B) The average MAC staining intensity of liver vasculature
in AdCAGsCD59-injected mice is reduced by 62.1% (**p,0.01) relative
to that of AdCAGGFP-injected mice (n=8).
doi:10.1371/journal.pone.0021621.g005
Figure 6. AdCAGsCD59 protects against human MAC deposi-
tion in the larger (non-capillary) blood vessels of the liver. (A)
Representative images indicating human MAC staining on the
endothelial cell layer of a large blood vessel of murine liver perfused
with mPECAM-1 antibody and NHS 7 days post-injection with
AdCAGsCD59 or AdCAGGFP. Corresponding brightfield images are also
shown (inset). (B) The average MAC staining intensity per endothelium
area of large liver vessels of AdCAGsCD59-injected mice is reduced by
41.4% (***p,0.001) relative to that of AdCAGGFP-injected mice (n=8).
doi:10.1371/journal.pone.0021621.g006
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delivered using a gene therapy approach to protect other tissues,
such as liver. In addition, we have demonstrated the ability of
sCD59 to protect cells, in this case endothelial cells, remote from
the site of vector transduction. Intraperitoneal injection of an
adenovirus expressing human sCD59 resulted in viral transduction
mainly along the peritoneal membrane at the periphery of the
liver. As sCD59 is produced, we postulate that it diffuses through
the extracellular matrix (ECM) towards the vasculature. We
further speculate that this mode of delivery will cause an
accumulation of sCD59 in the ECM around the endothelial cells,
potentially enhancing the probability of contact with C5b-8. That
protection is likely provided by sCD59 residing in the ECM or
close to the endothelial cell surface, and not sCD59 in the
circulation, is supported by the study design whereby we flush out
the mouse blood prior to perfusion with human serum. A similar
observation has been made for protection of brain capillary
endothelium from complement activation by C1 inhibitor in a
murine model of transient brain ischemia [32]. With this in mind,
we consider that this treatment approach is most appropriate for
those diseases in which complement activation occurs in
endothelial and/or other cell types of a specific tissue, such as is
the case in organ transplantation, AMD, diabetic retinopathy,
aHUS, and dense deposit disease. In future studies we would like
to determine whether or not sCD59 which is expressed from an
adenovirus vector residing in the liver and which enters the
bloodstream retains sufficient potency to prevent MAC deposition
on endothelial cells of the systemic vasculature, a finding
particularly relevant to atherosclerosis and systemic complement
activation associated with AMD.
Viral vectors such as adenovirus have been demonstrated to
express transgene products for the lifespan of mice [33] and have
been observed to exhibit a broad of tropism for different tissues,
particularly liver and kidney following intraperitoneal injection
[34]. However, we envisage that this approach could be extended
to AAV vectors which are generally considered safer, due to their
lower immunogenicity, for use in humans.
Inappropriate activation of complement is an underlying cause
of many diseases, and a number of these are known to involve
complement-mediated damage of endothelial cells [1]. An ex vivo
xenotransplantation simulation assay has previously shown human
MAC deposition along porcine endothelial cells [10]. Herein, we
have established an in vivo model of human MAC deposition on
endothelial cells of murine liver vasculature. This model may be
useful in evaluating anti-complement treatments for diseases in
which complement-induced damage to endothelial cells is known
to play a role. While caution needs to be exercised when data from
animal studies is used as an impetus to proceed to the clinic, as
many of the observations made in animal models have not been
confirmed in humans, the model employed in this study has the
advantage of permitting evaluation of anti-complement therapies
against human complement activation in an in vivo setting.
Despite detection of the perfused ‘‘activating’’ PECAM
antibody binding to endothelial cells in the other tissues examined
(retina, choroid, and aorta), we were unable to detect deposition of
MAC in any of these tissues. This may be due to differences in
local concentrations of endogenous complement regulators, such
as CD59, between these tissues. For example, murine CD59a has
shown some protection against human complement in vitro [35].
Further development of this model could include reproducing this
assay in mice deficient in one or more endogenous complement
regulators, such as mice deficient in CD59a/b [36].
In summary, we have generated an in vivo model of human
MAC deposition on endothelial cells of murine liver vasculature.
This model should prove useful for the testing of anti-complement
therapies for diseases known to involve complement-mediated
damage to endothelial cells, such as aHUS, dense deposit disease,
AMD, and diabetic retinopathy. In addition, we have shown the
potency of a non membrane-targeting sCD59 as a protective agent
against complement attack when delivered via a gene therapy
approach.
Methods
Animal use and care
Animal use in this study was in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. This study was approved by Tufts University Institu-
tional Animal Care and Use Committee (IACUC) protocol
B2009-03 and Tufts University Institutional Biosafety Committee
registration 2008-BRIA27. C57BL6/J and Balb/C mice aged 6–
10 weeks were purchased from Jackson Laboratories (Bar Harbor,
ME) and maintained in 12-hour dark light cycles in accordance
with federal, state, and local regulations. Mice were anesthetized
by intraperitoneal injection of 0.1 ml/10 g of ketamine (10 mg/
ml)/xylazine (1 mg/ml).
Ex vivo MAC deposition assay
C57BL6/J mice were anesthetized as described above. The
thoracic cage was opened, and blood flushed with 5 mL of sterile
PBS using a 21 gauge needle via the left ventricle. The descending
aorta was identified, extracted, and flattened. After a brief
incubation in ice-cold sterile PBS, the aorta was incubated in
50 mg/ml Goat anti-Mouse IgG (GAM) (Jackson ImmunoRe-
search Labs, West Grove, PA), 50 mg/ml Hamster anti-mouse
PECAM-1 (mPECAM-1) (clone 2H8, 1.4 mg/mL, prepared as
described previously [37]), or PBS for 1 hour at 4uC. Subsequent-
ly, the tissue was washed twice with ice-cold PBS for 5 minutes and
incubated with either 50% normal human serum (NHS)
(Complement Technology, Tyler, Tx) or heat-inactivated (56uC
for 1 hr) normal human serum (HI-NHS) in PBS
++ (0.15 mM
Ca
+, 0.5 mM Mg
+) for 8 minutes at 37uC. Aorta was rapidly
washed, and fixed overnight with 10% buffered formalin.
Intracardial delivery of mPECAM-1 antibody
C57BL6/J mice were anesthetized as described above. The
apex of the heart was located by palpation, and 200 mlo f
mPECAM-1 (250 mg) was delivered to the left ventricle using a 29
gauge needle. After 4 hours, mice were re-administered xylazine/
ketamine, the thoracic cage was opened, and blood flushed with
5 ml of sterile PBS using a 21 gauge needle via the left ventricle.
The descending aorta, the median and left lobes of the liver, and
both eyes were harvested and fixed overnight at 4uC in 10%
buffered formalin. For choroidal flatmounts, the same procedure
was employed in Balb/C mice.
Adenovirus construction
AdCAGsCD59 was constructed as previously described [21].
Briefly, the soluble form of CD59 was derived by manipulation of
the membrane bound human CD59 cDNA (IMAGE ID
#2988140, ATCC, Manassas, VA). Specifically, the sequence
encoding the C terminal 26 amino acids, representing the signal
sequence for attachment of the GPI anchor at Asp 77, was
removed by PCR amplification and cloned into pShCAG [38].
The resulting plasmid was recombined with pAdEasy-1 [39] in
BJ5183 to generate pAdCAGsCD59. 15 mg of pAdCAGsCD59
was linearized with PacI, ethanol precipitated, and transfected into
911 cells [40]. AdCAGsCD59 was propagated and purified using a
CD59 Attenuates Complement on Vascular Endothelium
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0.9610
11 particles/ml. AdCAGGFP was constructed as previously
described [38].
In vivo MAC perfusion assay
C57BL6/J mice were injected with 5610
9 particles of
AdCAGGFP or AdCAGsCD59 in 200 ml sterile PBS into the
intraperitoneal cavity. After 7 days, injected and uninjected mice
were anesthetized as described above. 200 ml of mPECAM-1
antibody was administered intracardially using a 29 gauge needle.
After 4 hours, mice were re-anesthetized, the thoracic cage opened
and blood flushed with 1 ml of sterile PBS using a 21 gauge needle
via the left ventricle. Immediately, the mouse was perfused with
1.5 ml of 90% NHS or HI-NHS solution in PBS
++, and incubated
for 15 minutes at 37uC. The median and left lobes of the liver and
both eyes were harvested and fixed overnight at 4uC in 10%
buffered formalin.
Tissue preparation
Fixed liver lobes and eyes were dehydrated by incubation in
15% and 30% sucrose. Liver lobes were trimmed to fit cryo molds
and eyes were dissected to remove the anterior segments. Tissue
was cryo-preserved and sectioned at 8 mm. For choroidal
flatmount, fixed Balb/C mouse eyes were briefly washed in PBS.
Eyes were dissected and the anterior segments were removed. The
optic nerve was detached from the retinal junction. Retina was
carefully peeled away from the posterior eyecup. Staining was
performed as described below, with the exception that 1% PBS-
Triton-X (PBS-T) was used in all incubations and washes. After
staining, a Von Graefe Knife (2630 mm; Miltex, Germany) was
used to initially separate the RPE/choroid layer from the sclera.
Separation was completed using a fine forceps to peel away the
RPE/choroid layer, sliding the knife underneath to prevent
tearing of the tissue. The RPE/choroid complex was then
flatmounted (Fluoromount-G; Southern Biotech, Birmingham,
Al) and coverslipped.
Immunofluorescent staining
Tissue slides were quickly dried and re-wetted with PBS. Slides
were permeabilized and blocked with 6% goat serum (Jackson
ImmunoResearch Labs) in 0.3% PBS-T for 30 minutes at room
temperature. Samples and slides were subsequently incubated with
Rabbit polyclonal anti-sC5b-9 neoantigen IgG (8.3 mg/ml,
Complement Technology) at a dilution of 1:400 in 0.3% PBS-T
for 2.5 hours at room temperature. Slides were subsequently
washed. Staining was completed by incubation with a CY3-
conjugated Goat anti-Rabbit IgG (Jackson ImmunoResearch
Labs) for 1 hour at room temperature. Slides were washed,
flatmounted and coverslipped. MAC staining was also conducted
using the same procedure with a separate antibody; mouse anti-
human C5b-9 (clone aE11; Abcam, Cambridge, MA), was used at
a 1:100 dilution , while the secondary antibody, CY3 Goat anti-
mouse IgG (Jackson ImmunoResearch Labs) was used at a 1:400
dilution. Staining for mPECAM-1 antibody delivery was per-
formed in a similar manner: slides were blocked with 6% goat
serum in 0.3% PBS-T for 30 minutes at room temperature and
subsequently incubated with a CY3 Goat anti-Armenian Hamster
IgG (Jackson ImmunoResearch Labs), at a 1:400 dilution in 0.3%
PBS-T for 1 hr at room temperature. Slides were subsequently
washed, flatmounted and coverslipped.
Image analysis
Imaging was performed using control-matched settings on an
Olympus IX51 microscope equipped with a Retiga 2000r camera.
Images were processed identically with Photoshop CS2 (Adobe;
Redwood City, CA). Overall Intensity and vessel intensity was
measured using ImageJ (NIH; Bethesda, Md). All images to be
analyzed were converted to 8-bit greyscale (intensity range=0–
255 IU). Background, as defined by max intensity in regions
without tissue (i.e. between large blood vessels), was subtracted
using the ‘Set Minimum’ function. To calculate overall intensity,
images of regions with representative staining were analyzed using
the ‘measure’ function to detect integrated density (total intensity).
Two images were analyzed per lobe, resulting in four images
averaged for each mouse (data point). Large blood vessels were
defined as those with a diameter larger than two cell widths, and
include arteries, arterioles, veins, and venules, but exclude
capillaries and sinusoids. To calculate vessel intensity, freehand-
selection tool was used to trace the outer boundary of the
endothelial cell-layer cross section. A corresponding brightfield
image was overlaid to ensure accurate region selection. Total
intensity (Iouter) and total area (Aouter) was calculated using the
measure function. The inner boundary of the endothelial cell-layer
cross-selection was subsequently traced and the total intensity
(Iinner) and total area (Ainner) measured. Area was converted
to mm
2 with the scale of 2.727 pixels/mm (200x zoom). To
calculate the average intensity per area (X, in IU/mm
2), the
following equation was used: X~ Iouter{Iinner ½  = Aouter{Ainner ½  .
10 random vessels were analyzed per lobe, resulting in 20 vessels
averaged for each mouse (data point).
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